Refractive outcome shifts toward myopia after combined surgery

Article

Postoperative refractive outcome shifts toward myopia in patients being treated for rhegmatogenous retinal detachment (RRD) with the combination of phacoemulsification and pars plana vitrectomy, compared with patients who underwent combined surgery for other vitreoretinal pathologies

Postoperative refractive outcome shifts toward myopia in patients being treated for rhegmatogenous retinal detachment (RRD) with the combination of phacoemulsification and pars plana vitrectomy, compared with patients who underwent combined surgery for other vitreoretinal pathologies, according to an article published online in the American Journal of Ophthalmology.

Researchers in South Korea conducted a retrospective observational case-control study of 55 patients. All of the patients had had a combined surgery between January 2007 and December 2012: 25 for RRD (the RRD group), and 30 for other vitreoretinal pathology (the control group). They found that the RRD group had a mean shift toward myopia of 0.35 D compared with the control group.

The mean difference between the predicted refractive outcome and the actual postoperative outcome was –0.43 D ± 0.67 (P = 0.046) in the RRD group and –0.08 D ± 0.53 (P = 0.767) in the control group. The mean preoperative intraocular pressure (IOP) was 11.44 mmHg ± 3.15 in the affected eye in the RRD group, and 13.16 mmHg ± 2.73 in the fellow eye (P = 0.045); there was no IOP difference in the affected eye (14.20 mmHg ± 2.95) and fellow eye (14.17 mmHg ± 3.50) in the control group (P = 0.974).

Postoperatively, there was no significant IOP difference in the affected and fellow eyes of both groups. In the RRD group, the refractive difference for all eyes correlated to IOP change (r = 0.659, r2 = 0.435, P

To read an abstract of the study, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.